First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia

Br J Haematol. 2020 Oct;191(2):e52-e55. doi: 10.1111/bjh.16992. Epub 2020 Jul 25.

Authors

Stephen Dong¹, Tarek Khedro¹, Pamela Ward², Louis Dubeau², Bassam Yaghmour³, Imran Siddiqi², George Yaghmour¹

Affiliations

¹ Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
² Department of Pathology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
³ Pulmonary, Critical Care, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.

No abstract available

Keywords: BRAF V600E mutation; T-cell prolymphocytic leukemia; dasatinib; vemurafenib; venetoclax (BCL-2 inhibitor).

Publication types

Case Reports
Letter

MeSH terms

Amino Acid Substitution
Humans
Leukemia, Prolymphocytic, T-Cell / genetics*
Leukemia, Prolymphocytic, T-Cell / therapy
Middle Aged
Mutation, Missense*
Proto-Oncogene Proteins B-raf / genetics*

Substances

BRAF protein, human
Proto-Oncogene Proteins B-raf

Grants and funding

P30 CA014089/CA/NCI NIH HHS/United States